A randomized phase II trial evaluating standard (50 mg/min) versus low (10 mg/min) infusion duration of gemcitabine as first-line treatment in advanced non-small-cell lung cancer patients who are not eligible for platinum-based chemotherapy

Lung Cancer

Volumn 52, Issue 3, 2006, Pages 319-325

  Cappuzzo, F ^a   Novello, S ^b   De Marinis, F ^c   Selvaggi, G ^b   Scagliotti, G V ^b   Barbieri, F ^d   Maur, M ^d   Papi, M ^e   Pasquini, E ^f   Bartolini, S ^a   Marini, L ^g   Crino L ^a  

^a BELLARIA HOSPITAL   (Italy)

^b SAN LUIGI GONZAGA HOSPITAL   (Italy)

^c SAN CAMILLO FORLANINI HOSPITAL   (Italy)

^d UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^e INFERMI HOSPITAL   (Italy)

^f Cervesi Hospital   (Italy)

^g Div Med Gen   (Italy)

Author keywords

Chemotherapy; Gemcitabine; Non small cell lung cancer

Indexed keywords

GEMCITABINE; PLATINUM;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ARTICLE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CARDIOTOXICITY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DOSE RESPONSE; DRUG FATALITY; DYSPNEA; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; LEUKOPENIA; LIVER TOXICITY; LUNG METASTASIS; LUNG NON SMALL CELL CANCER; LUNG TOXICITY; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEUROTOXICITY; NEUTROPENIA; PARESTHESIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; SKIN TOXICITY; STROKE; THROMBOCYTOPENIA;

AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; SURVIVAL RATE;

EID: 33747780795     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2006.03.004     Document Type: Article

References (33)

1. Jemal A., Murray T., Ward E., Samuels A., Tiwari R.C., Ghafoor A., et al. Cancer statistics, 2003. Ca Cancer J Clin 53 (2003) 5-26
2. Anderson H., Lund B., Bach F., Thatcher N., Walling J., and Hansen H. Gemcitabine plus best supportive care (BSC) vs BSC in inoperable non-small cell lung cancer: a randomized trial with quality of life as the primary outcome. Br J Cancer 83 (2000) 447-453
3. Crino L., Mosconi A.M., Scagliotti G., Selvaggi G., Novello S., Rinaldi M., et al. Gemcitabine as second-line treatment for advanced non-small-cell lung cancer: a phase II trial. J Clin Oncol 17 (1999) 2081-2085
4. Crino L., Scagliotti G.V., Ricci S., De Marinis F., Rinaldi M., Gridelli C., et al. Gemcitabine and cisplatin versus mitomycin, ifosfamide, and cisplatin in advanced non-small-cell lung cancer: a randomized phase III study of the Italian Lung Cancer Project. J Clin Oncol 17 (1999) 3522-3530
5. Sandler A.B., Nemunaitis J., Denham C., von Pawel J., Cormier Y., Gatzemeier U., et al. Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 18 (2000) 122-130
6. Scagliotti G.V., et al. Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J Clin Oncol 20 (2002) 4285-4291
7. Schiller J.H., et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346 (2002) 92-98
8. Le Chevalier T., Scagliotti G., Natale R., Danson S., Rosell R., Stahel R., et al. Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small-cell lung cancer: a meta-analysis of survival outcomes. Lung Cancer 47 (2005) 69-80
9. Hertel L.W., Boder G.B., Kroin J.S., Rinzel S.M., Poore G.A., Todd G.C., et al. Evaluation of the antitumor activity of gemcitabine (2′,2′-difluoro-2′-deoxycytidine). Cancer Res 50 (1990) 4417-4422
10. Anderson H., Lund B., Bach F., Thatcher N., Walling J., and Hansen H. Single-agent activity of weekly gemcitabine in advanced non-small-cell lung cancer: a phase II study. J Clin Oncol 12 (1994) 1821-1826
11. Gatzemeier U., Shepherd F.A., Le Chevalier T., Weynants P., Cottier B., Groen H.J., et al. Activity of gemcitabine in patients with non-small cell lung cancer: a multicentre, extended phase II study. Eur J Cancer A 32 (1996) 243-248
12. Heinemann V., Hertel L.W., Grindey G.B., and Plunkett W. Comparison of the cellular pharmacokinetics and toxicity of 2′,2′-difluorodeoxycytidine and 1-β-d-arabinofuranosylcytosine. Cancer Res 48 (1988) 4024-4031
13. Grunewald R., Kantarjian H., Keating M.J., Abbruzzese J., Tarassoff P., and Plunkett W. Pharmacologically directed design of the dose rate and schedule of 2′,2′-difluorodeoxycytidine (gemcitabine) administration in leukaemia. Cancer Res 50 (1990) 6823-6826
14. Abbruzzese J.L., Grunewald R., Weeks E.A., Gravel D., Adams T., Nowak B., et al. A phase I clinical, plasma, and cellular pharmacology study of gemcitabine. J Clin Oncol 9 (1991) 491-498
15. Tempero M., Plunkett W., Ruiz Van Haperen V., Hainsworth J., Hochster H., Lenzi R., et al. Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. J Clin Oncol 21 (2003) 3402-3408
16. Von Hoff D.D. Activity of gemcitabine in a human tumor cloning assay as a basis for clinical trials with Gemcitabine: San Antonio Drug Development Team. Invest New Drugs 14 (1996) 265-270
17. Csoka K., Liliemark J., Larsson R., and Nygren P. Evaluation of the cytotoxic activity of gemcitabine in primary cultures of tumor cells from patients with hematologic or solid tumors [4 suppl 11]. Semin Oncol 22 (1995) 47-53
18. Fossella F.V., Lippman S.M., Shin D.M., Tarassoff P., Calayag-Jung M., Perez-Soler R., et al. Maximum-tolerated dose defined for single-agent gemcitabine: a phase I dose-escalation study in chemotherapy-naive patients with advanced non-small-cell lung cancer. J Clin Oncol 15 (1997) 310-316
19. Brand R., Capadano M., and Tempero M. A phase I trial of weekly gemcitabine administered as a prolonged infusion in patients with pancreatic cancer and other solid tumors. Invest New Drugs 15 (1997) 331-341
20. Touroutoglou N., Gravel D., Raber M.N., Plunkett W., and Abbruzzese J.L. Clinical results of a pharmacokinetically-based strategy for higher dosing of gemcitabine in patients with solid tumors. Ann Oncol 9 (1998) 1003-1008
21. Miller A.B., Hoogstraten B., Staquet M., and Winkler A. Reporting results of cancer treatment. Cancer 47 (1981) 207-214
22. Clinical practice guidelines for the treatment of unresectable non-small-cell lung cancer: adopted on May 16, 1997 by the American Society of Clinical Oncology. J Clin Oncol 15 (1997) 2996-3018
23. Common toxicity criteria (1993), National Institute of Health, Cancer Therapy Evaluation Program, Division of Cancer Treatment, Bethesda
24. Baka S., Ashcroft L., Anderson H., Lind M., Burt P., Stout R., et al. Randomized phase II study of two gemcitabine schedules for patients with impaired performance status (Karnofsky performance status ≤ 70) and advanced non-small-cell lung cancer. J Clin Oncol 23 (2005) 2136-2144
25. Chun P.Y., Feng F.Y., Scheurer A.M., Davis M.A., Lawrence T.S., and Nyati M.K. Synergistic effects of gemcitabine and gefitinib in the treatment of head and neck carcinoma. Cancer Res 66 (2006) 981-988
26. Knight L.A., Di Nicolantonio F., Whitehouse P., Mercer S., Sharma S., Glaysher S., et al. The in vitro effect of gefitinib ('Iressa') alone and in combination with cytotoxic chemotherapy on human solid tumours. BMC Cancer 23 (2004) 4-83
27. Bruns C.J., Harbison M.T., Davis D.W., Portera C.A., Tsan R., McConkey D.J., et al. Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms. Clin Cancer Res 6 (2000) 1936-1948
28. Giaccone G., Herbst R.S., Manegold C., Scagliotti G., Rosell R., Miller V., et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 1. J Clin Oncol 22 (2004) 777-784
29. Herbst R.S., Giaccone G., Schiller J.H., Natale R.B., Miller V., Manegold C., et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 2. J Clin Oncol 22 (2004) 785-794
30. Gatzemeier U., et al. Results of a phase III trial of erlotinib (OSI-774) combined with cisplatin and gemcitabine (GC) chemotherapy in advanced non-small cell lung cancer (NSCLC) [abstr]. Proc Am Soc Clin Oncol 23 (2004) 617
31. Herbst R.S., et al. A phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small cell lung cancer. J Clin Oncol 23 (2005) 5892-5899
32. Cappuzzo F., Hirsch F.R., Rossi E., Bartolini S., Ceresoli G.L., Bemis L., et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small cell lung cancer. J Natl Cancer Inst 97 (2005) 643-655
33. Paez J.G., Janne P.A., Lee J.C., Tracy S., Greulich H., Gabriel S., et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304 (2004) 1497-1500